Published on 11 Feb 2022 on Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug,...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Eli Lilly And Company (NYSE: LLY) said the U.S. Food and Drug Administration's Oncology Drug Advisory Committee, which reviewed the biologic license application filed for sintilimab, voted that additional clinical trial(s) should be required to demonstrate applicability to the U.S. population and U.S. medical practice prior to a final regulatory decision.